HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

Giovanni Scambia, Mark Mchugh, Steven Sieber, Shiquan He, Zheyang Wu, Paul Fiedler, Shohreh Shahabi, Cristiano Ferlini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

30 Citazioni (Scopus)

Abstract

Ovarian cancer is the most lethal gynecologic malignancy. Recently, NACT (Neo Adjuvant Chemotherapy) has been tested as alternative approach for the management of ovarian cancer patients. A biological predictor helpful in selecting patients for NACT would be desirable. This study was aimed at identifying actionable mechanisms of resistance to NACT. Expression of a panel of microRNAs was screened in a discovery set of 85 patients. Analysis of the potential targets was conducted in the same RNAs by calculating significant correlations between microRNAs and genes. Quantitative fluorescent immunohistochemistry was employed in a validation set of 109 patients. MiR-193a-5p was significantly overexpressed in the NACT setting. Analysis of its potential targets demonstrated that this microRNA is also significantly correlated with HGF and MET genes. Analysis of protein expression in samples taken before and after NACT demonstrated that both HGF and c-Met are increased after NACT. Patients who relapse shortly after NACT exhibited the highest relative basal expression of both HGF and c-Met, while the opposite phenomenon was observed in the best responders. Mir-193a-5p, HGF and c-Met expression may help select eligible patients for this modality of treatment. Moreover, inhibitors of this pathway may improve the efficacy of NACT.
Lingua originaleEnglish
pagine (da-a)4855-4867
Numero di pagine13
RivistaOncotarget
Volume5
Stato di pubblicazionePubblicato - 2014

Keywords

  • hgf/c-met axis
  • ovarian cancer

Fingerprint Entra nei temi di ricerca di 'HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer'. Insieme formano una fingerprint unica.

Cita questo